Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX–Bevacizumab or FOLFIRI–Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study

201299 citationsJournal Articlebronze Open Access

Authors

Johanna C. Bendell · Sarah Cannon

Tanios Bekaii‐Saab · The Ohio State University

Allen Lee Cohn · Rocky Mountain Cancer Centers

Herbert I. Hurwitz · Duke University

M. Kozloff · Ingalls Memorial Hospital

Haluk Tezcan · Kootenai Medical Center

Nancy Roach ·

Abstract

In first-line mCRC patients, the FOLFOX-bevacizumab and FOLFIRI-bevacizumab regimens were associated with similar treatment patterns and clinical outcomes.

Topics & Keywords

Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Hepatocellular Carcinoma Treatment and Prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Oncologist

Volume 17, Issue 12, pp. 1486-1495

DOI: 10.1634/theoncologist.2012-0190

Field-Weighted Citation Impact: 6.64